Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 0.79
(-5.94%)
SEK 0.79
(-5.94%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 26.82 Million SEK | -292.11% |
| 2022 | 28.84 Million SEK | 55.43% |
| 2021 | 18.56 Million SEK | 340.23% |
| 2020 | 4.21 Million SEK | -21.49% |
| 2019 | 5.37 Million SEK | -12.51% |
| 2018 | 6.13 Million SEK | 17.7% |
| 2017 | 5.21 Million SEK | -20.53% |
| 2016 | 6.56 Million SEK | 53.07% |
| 2015 | 4.28 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | -29.3 Million SEK | -530.87% |
| 2023 Q3 | 6.6 Million SEK | 122.55% |
| 2023 Q4 | 6.6 Million SEK | 0.0% |
| 2023 FY | -55.41 Million SEK | -292.11% |
| 2023 Q1 | 6.8 Million SEK | 129.88% |
| 2022 Q4 | -22.76 Million SEK | -390.0% |
| 2022 Q2 | -23.81 Million SEK | -462.17% |
| 2022 Q1 | 6.57 Million SEK | 130.0% |
| 2022 FY | 28.84 Million SEK | 55.43% |
| 2022 Q3 | 7.84 Million SEK | 132.96% |
| 2021 Q2 | -22.73 Million SEK | -215.59% |
| 2021 FY | 18.56 Million SEK | 340.23% |
| 2021 Q1 | 19.66 Million SEK | 6234.3% |
| 2021 Q4 | -21.91 Million SEK | -420.56% |
| 2021 Q3 | 6.83 Million SEK | 130.07% |
| 2020 Q3 | 310.5 Thousand SEK | -84.29% |
| 2020 Q2 | 1.97 Million SEK | 21.98% |
| 2020 Q1 | 1.62 Million SEK | -32.58% |
| 2020 FY | 4.21 Million SEK | -21.49% |
| 2020 Q4 | 310.5 Thousand SEK | 0.0% |
| 2019 Q2 | 925 Thousand SEK | 123.97% |
| 2019 Q1 | 413 Thousand SEK | -83.06% |
| 2019 FY | 5.37 Million SEK | -12.51% |
| 2019 Q4 | 2.4 Million SEK | 45.9% |
| 2019 Q3 | 1.64 Million SEK | 78.05% |
| 2018 Q2 | 1.46 Million SEK | -6.86% |
| 2018 FY | 6.13 Million SEK | 17.7% |
| 2018 Q4 | 2.43 Million SEK | 191.28% |
| 2018 Q3 | 837 Thousand SEK | -42.91% |
| 2018 Q1 | 1.57 Million SEK | 460.18% |
| 2017 Q3 | 2.39 Million SEK | 47.07% |
| 2017 Q1 | 1.62 Million SEK | 158.49% |
| 2017 FY | 5.21 Million SEK | -20.53% |
| 2017 Q4 | -437 Thousand SEK | -118.25% |
| 2017 Q2 | 1.62 Million SEK | 0.0% |
| 2016 Q4 | 630 Thousand SEK | 0.0% |
| 2016 FY | 6.56 Million SEK | 53.07% |
| 2015 FY | 4.28 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 116.692% |
| Ziccum AB (publ) | -23.28 Million SEK | 215.181% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 92.255% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 35.815% |
| Mendus AB (publ) | 28.48 Million SEK | 5.848% |
| Genovis AB (publ.) | 54 Million SEK | 50.332% |
| Intervacc AB (publ) | -13.79 Million SEK | 294.44% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1135.421% |
| Active Biotech AB (publ) | -1.67 Million SEK | 1701.254% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -169.206% |
| Aptahem AB (publ) | 2.63 Million SEK | -919.559% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 884.011% |
| Kancera AB (publ) | -1.96 Million SEK | 1464.936% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -34732.468% |
| Fluicell AB (publ) | 1.73 Million SEK | -1443.211% |
| Saniona AB (publ) | 11.78 Million SEK | -127.663% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 624.155% |
| Biovica International AB (publ) | 6.87 Million SEK | -290.01% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 215.196% |
| AcouSort AB (publ) | 8.38 Million SEK | -219.716% |
| Xintela AB (publ) | 78 Thousand SEK | -34285.897% |
| Abliva AB (publ) | -35.66 Million SEK | 175.207% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 118.258% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -855.504% |
| OncoZenge AB (publ) | 3000.00 SEK | -893933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 1489.689% |
| 2cureX AB (publ) | -37.48 Million SEK | 171.547% |
| CombiGene AB (publ) | -21.29 Million SEK | 225.975% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 6440.662% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 97.626% |
| Camurus AB (publ) | 1.58 Billion SEK | 98.303% |
| Corline Biomedical AB | 28.38 Million SEK | 5.493% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 121.853% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 177.934% |
| I-Tech AB | 27.56 Million SEK | 2.703% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 62.198% |
| Cyxone AB (publ) | 2.61 Million SEK | -927.231% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -688.158% |
| Biosergen AB | -456 Thousand SEK | 5981.798% |
| Cantargia AB (publ) | -3.45 Million SEK | 877.195% |
| NextCell Pharma AB | -43.74 Million SEK | 161.308% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 391.723% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -139.083% |
| Nanologica AB (publ) | -76 Thousand SEK | 35390.789% |
| SynAct Pharma AB | -778 Thousand SEK | 3547.429% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 13996.891% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 307.561% |
| Lipum AB (publ) | 53 Thousand SEK | -50505.66% |
| BioInvent International AB (publ) | 71.46 Million SEK | 62.468% |
| Alzinova AB (publ) | 19.87 Million SEK | -34.955% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 26.111% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1733.263% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 178906.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -1517.672% |
| Simris Alg AB (publ) | 2 Million SEK | -1236.373% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 849.19% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 24.209% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 2656.816% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -756.08% |